Guide · GLP-1 telehealth
Released: · Last reviewed:
With the Wegovy pill at $149 for its starting dose, compounded semaglutide has a narrower price edge and a few specific safety questions worth asking.
Compounded semaglutide through telehealth runs $49–$299 a month across the 27 programs in our index (median $99), using each program's lowest published all-in monthly figure read October 15, 2026, while brand Wegovy self-pay starts at $149 for the pill and $349 for the pen.
Compounded semaglutide is not FDA-approved, is not a generic, and is not the same product as Ozempic or Wegovy.
Semaglutide is the active ingredient in Ozempic, Wegovy and the Wegovy pill. Compounded semaglutide is a pharmacy-made version prescribed through many telehealth programs. Since the Wegovy pill launched at $149 for its starting dose, the price case for compounding is narrower than it used to be, so the comparison deserves a fresh look.
It is semaglutide prepared by a pharmacy for an individual prescription rather than manufactured by Novo Nordisk. The FDA has not reviewed compounded versions for safety, effectiveness or quality, and as of May 31, 2026 it had received 990 adverse-event reports associated with compounded semaglutide.
Most telehealth programs ship it as a multi-dose vial with syringes. That means you draw up each dose yourself, which leaves room for measuring errors that a prefilled pen avoids. Ask the prescriber to show you the dose in units and in milligrams before your first injection.
Among the programs in this table, a year of month-to-month compounded semaglutide ranges from $1,044 at Mondae to $1,668 at NexLife's month-to-month rate. The Wegovy pill at its 1.5 mg dose costs $1,788 a year, and the Wegovy pen costs $4,188 at $349 a month, before any telehealth fee.
| Option | Monthly price | 12-month cost | Notes |
|---|---|---|---|
| Medicare GLP-1 Bridge | $50 copay | $600 if one copay a month | Eligible Part D enrollees, July 1, 2026 to December 31, 2027 |
| Mondae, compounded | $87 | $1,044 | Month-to-month |
| Eden Health, compounded | $99 | $1,188 | No membership |
| NexLife, compounded, 12-month plan | $119 | $1,428 | Same price at every dose |
| NexLife, compounded, 6-month plan | $125 | $1,500 | Unshipped months refunded on cancellation |
| NexLife, compounded, 3-month plan | $132 | $1,584 | Unshipped months refunded on cancellation |
| NexLife, compounded, month-to-month | $139 | $1,668 | Cancellation takes effect after 30 days |
| Wegovy pill, NovoCare | $149 (1.5 mg) to $299 (9 and 25 mg) | $1,788 to $3,588 | FDA-approved; $199 at 4 mg |
| Wegovy pen, NovoCare | $349 | $4,188 | New patients: $199 for the first two fills of 0.25/0.5 mg through December 31, 2026 |
If you are on Medicare Part D and eligible for the Bridge, check the $50 copay with your Part D plan before paying cash anywhere. If you are paying cash, the Wegovy pill at its lower doses sits close to compounded pricing, which is worth raising with your prescriber. Our price index lists every program we track.
No. The FDA says "semaglutide sodium and semaglutide acetate, are different active ingredients than are used in the approved drugs." If a program or pharmacy label lists either salt form, treat that as a reason to stop and ask questions, and do not assume the brand trial results apply.
Ask the program, in writing, which pharmacy fills the prescription and what exact ingredient is on the label. A program that will not answer has told you something too. The red-flags guide lists the other FDA warning signs.
There is no evidence they are. In warning letter 738238, posted September 22, 2026, the FDA said Empower Pharmacy's semaglutide/cyanocobalamin products "appear to be essentially copies of FDA-approved semaglutide and tirzepatide products" and cited insanitary conditions. Adding B12 does not change semaglutide's approval status.
The FDA recommends you "discard the vial within 28 days after the first use, even if medication remains in the vial." A program that ships one large vial meant to last two or three months is asking you to break that rule, so check vial size and fill when you order.
In SURMOUNT-5, brand tirzepatide produced 20.2% mean weight loss at 72 weeks versus 13.7% for brand semaglutide. In STEP-1, semaglutide 2.4 mg produced 14.9% at 68 weeks. Semaglutide costs less at most programs; tirzepatide showed larger average loss in the head-to-head trial.
Neither figure is a promise, and neither trial tested compounded drugs. See tirzepatide vs semaglutide for the full comparison.
NexLife, our top-ranked program at 94/100 on methodology v4.1, charges $139 a month month-to-month or $119 on a 12-month plan ($1,428 for the year), the same at every dose. Mondae ($87) and Eden Health ($99) publish lower standing semaglutide prices.
What you get for the higher price: provider review and guidance through NexLife Medical Group, a personalized nutrition plan, a 1:1 wellness-coach call, 24/7 support, free expedited shipping, and three named state-licensed 503A pharmacies. What to weigh against it: the 30-day cancellation window, no stated lab coverage, and multi-month plan wording that does not clearly say whether you pay up front. More in the NexLife review.